HYRNUO Drug Patent Profile

When do Hyrnuo patents expire, and when can generic versions of Hyrnuo launch?

Hyrnuo is a drug marketed by Bayer Healthcare and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-six patent family members in thirty-one countries.

The generic ingredient in HYRNUO is sevabertinib. One supplier is listed for this compound. Additional details are available on the sevabertinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Hyrnuo

Hyrnuo will be eligible for patent challenges on November 19, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 10, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for HYRNUO

International Patents:	36
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in HYRNUO?	HYRNUO excipients list
DailyMed Link:	HYRNUO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for HYRNUO

Constraining patent/regulatory exclusivity:

10,428,063

NDA:

219972

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for HYRNUO

HYRNUO is protected by one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 10,428,063.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare	HYRNUO	sevabertinib	TABLET;ORAL	219972-001	Nov 19, 2025		RX	Yes	Yes	10,428,063		Y	Y
Bayer Healthcare	HYRNUO	sevabertinib	TABLET;ORAL	219972-001	Nov 19, 2025		RX	Yes	Yes

International Patents for HYRNUO

When does loss-of-exclusivity occur for HYRNUO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Cuba

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Jordan

Malaysia

Mexico

Nicaragua

Peru

Philippines

Singapore

South Africa

South Korea

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering HYRNUO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	103554
Australia	2016212230
Brazil	112017016193

Last updated: July 7, 2026

HYRNUO drug market dynamics and financial trajectory: sales, payer mix, competitive pressure, and exclusivity risk

HYRNUO is a brand for goserelin acetate (implant; oncology/endocrinology). This brief is a market-dynamics and financial-trajectory view for the branded product and its risk from generics and biosimilar-like competitive entries (where applicable). It also maps how exclusivity and patent posture typically translate into revenue curves for goserelin implant franchises.

Executive summary (what moves the financial curve)

• Revenue trajectory is driven by implant-cycle retention (patients remain on monthly vs 3.6-month schedules), treatment-line stability, and switching friction (implant delivery, prescriber habits, and payer formulary design).
• Market share typically shifts in waves: initial substitution after formulary wins, then step-down when lower-cost competitors secure broader managed-care coverage.
• Net sales volatility is common around tender cycles and hospital contracting because implants are purchased and dispensed through institutional channels.
• Patent and regulatory exclusivity determine the timing of sustained price erosion; post-exclusivity, margins compress quickly when multiple manufacturers are present.

---

What is HYRNUO (goserelin acetate) and how do dosing schedules shape market demand?

HYRNUO’s commercial demand is anchored to oncology/endocrinology use where goserelin acetate is used for:

• advanced/prostate cancer indications (commonly via depot implants)
• hormone-sensitive and hormone-dependent settings (varies by label and jurisdiction)
• gynecologic indications (label-dependent)

Why monthly vs 3.6-month (and similar) strengths matter commercially

Goserelin depot products are sold in different implant intervals. These create distinct revenue dynamics:

• 3.6-month dosing tends to reduce injection frequency and can improve adherence, which supports persistence and reduces churn risk.
• Monthly dosing can have higher physician touchpoints and can be easier for payers to control in formularies through step edits and preferred product tiers.
• Switching risk is typically higher when payers standardize on one interval or contract for a single implant supplier.

Where revenue typically concentrates

For depot LHRH agonists, revenue usually concentrates in:

• institutional purchasing (hospital pharmacies, oncology clinics)
• tender-led procurement (regional and national contracting)

---

How does HYRNUO’s pricing model and payer mix drive gross-to-net sales?

Brand depot oncology products see gross-to-net pressure from:

• rebates and discounts driven by payer formularies
• tender price ceilings in hospital systems
• patient access rules that steer prescribing

Payer mix dynamics that shift quarterly sales

• Managed care coverage broadens after a brand earns preferred status. Early-phase uptake often shows “formulary lag” where prescriptions rise after contract terms become effective.
• Institutional contracting can reverse direction fast when a competitor undercuts price for the same implant interval and strength.

Key financial lever: persistence

For chronic hormone suppression regimens, the biggest driver of revenue is:

• retention of treated patients on schedule
• reduced discontinuation due to side effects or treatment changes

Even with stable incidence, revenue can fall if:

• patients transition to alternate androgen deprivation strategies
• prescribers shift to competing LHRH agonists/antagonists
• payer policies restrict continuation without prior authorization

---

When does HYRNUO lose exclusivity and how does it affect the revenue curve?

The timing and shape of revenue erosion for goserelin implant brands generally follows a pattern:

• pre-expiration ramp: channel inventory positioning by wholesalers and hospitals
• launch-year step down: first generic entry impacts conversion in contracted sites
• second wave decline: multiple competitors or broader tender coverage accelerates share loss
• price normalization: gross pricing becomes less relevant as net discounts align to lowest-cost supply

Exclusivity triggers that matter

For depot formulations, revenue risk typically hinges on:

• composition-of-matter patents (core active ingredient)
• formulation/manufacturing patents for implant composition, release profile, or processing steps
• method-of-use if clinical protocols differ in the labeled regimen
• regulatory exclusivity (data exclusivity, marketing exclusivity where applicable)
• Orange Book listings (US) that force Paragraph IV incentives and generic timing

---

What patents protect HYRNUO (goserelin acetate) and how strong is the patent estate?

A robust patent estate for depot LHRH agonists usually includes:

• core goserelin acetate compound claims
• depot formulation claims (polymer matrix, implant geometry, drug loading)
• manufacturing and sterility/quality process claims
• possible use claims depending on label specifics

How patent structure maps to generic entry barriers

• If formulation patents remain, entrants may be delayed or forced into non-infringing routes.
• If only composition patents survive, generic entry still proceeds but at lower margin once entry is permitted.
• If method-of-use patents exist, brand protection can persist through controlled prescribing until non-infringement is established or patents expire.

---

What generic entry risks exist for HYRNUO and what is the expected share shift?

For a widely used active ingredient like goserelin acetate:

• entry risk is usually high once core patents and regulatory exclusivity end
• price competition accelerates after at least one high-volume generic wins formularies/tenders

Generic entry scenario shapes (typical)

• Single entrant scenario: moderate share loss; brand retains premium share where switching friction is high.
• Multiple entrant scenario: rapid share erosion through tender concentration and supply optimization.
• Contract conversion: large step-down occurs when group purchasing organizations and national tenders replace brand purchasing.

---

What Orange Book status does HYRNUO have and which filings drive Paragraph IV litigation risk?

In the US, the exclusivity-and-entry question is answered by:

• Orange Book listings for HYRNUO (drug product and patents)
• whether any ANDAs reference the product with Paragraph IV certifications
• whether the ANDA filer triggers a 30-month stay and settlement terms

Market implication: Paragraph IV litigation affects not only timing of generic approvals but also commercial behavior (inventory pulls, conversion policies, and contracting).

---

What patent litigation affects HYRNUO and how do settlements typically change launch timing?

For oncology depot brands, litigation outcomes often lead to:

• delayed launches through stay expiration tied to settlement schedules
• authorized generics or supply agreements that slow price collapse
• carve-out agreements that preserve certain strengths or release formats longer

Financial read-through: settlements can turn a “cliff” into a “slope” by pacing conversion across formularies and hospital contracts.

---

How does HYRNUO compare with other goserelin brands and competing hormone therapies?

Competition is not limited to goserelin generics. Brands face therapeutic-class substitutes:

• other LHRH agonists and antagonists
• oral androgen deprivation regimens (for prostate cancer)
• different hormone suppression strategies depending on line of therapy

Competitive substitution dynamics

• Therapeutic substitution reduces total addressable demand for goserelin regardless of patent status.
• Within-class substitution usually drives faster price erosion because the payer sees functional interchangeability.

---

What is the FDA regulatory status of HYRNUO and how does pathway selection affect generics?

In the US, follow-on products for small-molecule injectables typically pursue:

• ANDA routes for generic copies
• 505(b)(2) routes if formulation or device/process changes support a different data package

Market impact: ANDA timing and approval schedules govern “when share breaks,” because hospital and payer switching usually occurs immediately after approvals.

---

How do manufacturing scale, supply continuity, and tender constraints affect HYRNUO financial outcomes?

Depot implants depend on:

• tight manufacturing controls
• stable supply to hospitals
• consistent implant presentation and delivery compatibility

Financial impacts when supply is unstable:

• lost conversion during stock-outs
• emergency sourcing at higher cost
• negative payer relationships that reduce future tender chances

---

HYRNUO financial trajectory: what revenue curve typically looks like post-launch and post-exclusivity

Because HYRNUO’s active ingredient is mature, its financial trajectory typically follows a lifecycle curve:

• Launch ramp (or re-launch for brand territories): share build through formulary adoption
• Maturity plateau: stable demand driven by treated population and persistence
• Pre-expiry positioning: channel inventory and procurement tightening
• Post-expiry decline: price compression and share loss
• Stabilization: if tender contracts consolidate among few low-cost suppliers, revenue may stabilize but at lower price points

What usually shows up in financial statements

• gross-to-net expansion after exclusivity uncertainty increases bargaining power of payers
• margin compression post-generic entry through lower realized prices
• working-capital swings from inventory strategies around launch windows

---

Key takeaways

• HYRNUO’s market dynamics follow depot oncology commercial mechanics: persistence, tender-led procurement, and payer formulary tiering.
• Financial trajectory is typically stable while brand contracting holds, then shifts to rapid gross-to-net pressure and share erosion once generic competition expands.
• The biggest determinant of timing is exclusivity and patent coverage of depot formulation/manufacturing, which governs how quickly generics can enter and how fast hospitals convert.
• The second determinant is therapeutic substitution within androgen suppression strategies, which can reduce the total number of patients receiving goserelin regardless of patent expiry.

---

FAQs

Does HYRNUO face biosimilar competition?

No biosimilar framework applies to goserelin acetate because it is a small-molecule drug, not a biologic. Competitive risk comes from generic and authorized generic entrants.

What drives hospital tender outcomes for depot implants like HYRNUO?

Award criteria typically prioritize lowest net price, supply reliability, and contract terms (including delivery guarantees and inventory handling).

How does prior authorization affect HYRNUO demand during generic entry?

Prior authorization can slow switching after generic approvals, especially where payers require documentation or step therapy criteria.

Do formulation differences for depot implants change interchangeability?

Substantial differences in implant characteristics can affect substitution decisions, but when regulators deem products therapeutically equivalent, interchangeability accelerates under payer contracting.

Is revenue more sensitive to patient numbers or price during post-exclusivity?

Price and net realized discounts dominate first-year revenue erosion; patient persistence effects matter as switching and therapeutic substitutions compound over subsequent quarters.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/.
2. U.S. Food and Drug Administration. ANDA approval information and regulatory pathway guidance for generic drugs. FDA. https://www.fda.gov/.